 |
2 Diseases |  |
0 Trials |
|
0 Trials |  |
9 News |  |
- || ProLindac (AP 5346) / Abeona Therap, milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead, aldoxorubicin (INNO-206) / LadRx
Review, Journal: Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release. (Pubmed Central) - Aug 10, 2024
These prodrugs include albumin-binding prodrugs (Aldoxorubicin and DK049), polymeric micelle (NC-6300), polymer conjugates (ProLindac
- ||| milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead
Trial termination: A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma (clinicaltrials.gov) - Mar 4, 2020
P1/2, N=17, Terminated, Sponsor: Immunomedics, Inc.
These prodrugs include albumin-binding prodrugs (Aldoxorubicin and DK049), polymeric micelle (NC-6300), polymer conjugates (ProLindac Completed --> Terminated; Study was terminated due to lack of efficacy
- | milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead
Enrollment change, Trial termination: Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL (clinicaltrials.gov) - Feb 20, 2020
P1/2, N=13, Terminated, Sponsor: Immunomedics, Inc.
Completed --> Terminated; Study was terminated due to lack of efficacy N=30 --> 13 | Active, not recruiting --> Terminated; Study was terminated due to lack of efficacy, as a result, the stability program for the drug product was discontinued
- | milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead
Enrollment change: A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 23, 2015
P1/2, N=17, Completed, Sponsor: Immunomedics, Inc.
N=30 --> 13 | Active, not recruiting --> Terminated; Study was terminated due to lack of efficacy, as a result, the stability program for the drug product was discontinued N=42 --> 17
- | milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead
Enrollment closed: Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL (clinicaltrials.gov) - Sep 8, 2015
P1/2, N=30, Active, not recruiting, Sponsor: Immunomedics, Inc.
N=42 --> 17 Recruiting --> Active, not recruiting
- | milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead
Enrollment open: Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL (clinicaltrials.gov) - May 6, 2014
P1/2, N=30, Recruiting, Sponsor: Immunomedics, Inc.
Recruiting --> Active, not recruiting Suspended --> Recruiting
- | milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead
Trial completion: A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma (clinicaltrials.gov) - Jan 21, 2014
P1/2, N=42, Completed, Sponsor: Immunomedics, Inc.
Suspended --> Recruiting Suspended --> Completed
- milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead
Trial suspension: Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL (clinicaltrials.gov) - Jun 17, 2013
P1/2, N=30, Suspended, Sponsor: Immunomedics, Inc.
Suspended --> Completed Recruiting --> Suspended
- milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead
New P1/2 trial: Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL (clinicaltrials.gov) - Apr 24, 2012
P1/2, N=30, Suspended, Sponsor: Immunomedics, Inc.